Evotec SE has announced the nomination of a small-molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall SA. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need. The collaboration, established in 2022, leverages Evotec’s fully integrated, AI/machine learning enhanced discovery and preclinical development platforms.
DNA methylation, catalyzed by DNMT enzymes, is a central epigenetic mechanism frequently disrupted in cancer, where aberrant hypermethylation contributes to tumor suppressor gene silencing. Researchers from Nankai University reported the discovery and preclinical characterization of [I], a selective DNMT1 degrader in models of acute myeloid leukemia (AML).
Quiver Bioscience Inc. has received a multi-year grant from the National Institutes of Health (NIH) to advance its lead Nav1.7-targeted antisense oligonucleotide (ASO), QV-2421, through IND-enabling studies and first-in-human trials for chronic neuropathic pain.
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance the lead program CYT-X300 to the clinic in the treatment of EGFR-positive solid tumors. The company’s pan gamma delta (γδ) TCEs are designed to overcome problems with cytokine release syndrome, on-target effects on healthy cells, and the excessive activation of CD3 that have occurred with earlier bispecific antibodies that bind to the CD3 receptor on T cells.
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.
Sanyou Biopharmaceuticals Co. Ltd. has prepared and tested new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic agent through linker reported to be useful for the treatment of lung and stomach cancer.
Antibody-drug conjugates (ADCs) comprising an antibody targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug have been described in a Shanghai Pharmaceuticals Holding Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has patented new crystalline salt forms of poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Vanderbilt University has identified new 1-heteroarylazetidine-3-heteroarylmethylcarboxamide 5-HT2B receptor antagonists reported to be useful for the treatment of myocardial infarction, systemic sclerosis and pulmonary arterial hypertension.
RSS
